Vanguard Portfolio Management’s Caris Life Sciences CAI Stock Holding History
Bought
Maintained
Sold
Other funds holding CAI
JHWEPV
B
SSP
PC
Vanguard Portfolio Management's CAI Position: Q2 2026 in Review
Vanguard Portfolio Management increased its Caris Life Sciences (CAI) stake by 29% in Q2 2026, buying an estimated $19.4M and bringing the position to 4,844,431 shares worth $86.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1557.
Vanguard Portfolio Management first reported a position in CAI in Q1 2026 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.
- Vanguard Portfolio Management held 4,844,431 shares of Caris Life Sciences worth $86.3M as of Q2 2026.
- Vanguard Portfolio Management bought 1,085,969 Caris Life Sciences shares in Q2 2026, an estimated $19.4M.
- Caris Life Sciences made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1557 holding.
- Vanguard Portfolio Management first reported a position in Caris Life Sciences in Q1 2026 and has held it in 2 quarters since.
- 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.
Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.